In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
|Videos|January 26, 2022
Assessing the Future of Inclisiran in Clinical, Pharmacy Settings
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses projections for inclisiran’s use in clinical and pharmacy settings.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol management.
During the interview, Lepor discussed projections for the use of inclisiran in clinical and pharmacy settings.
Advertisement
Related to this article
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
3
CagriSema Tied to 25% Weight Loss in Women, Post Hoc Data Show
4
Kidney Week 2026: What to Know for Nephrology's Biggest Meeting
5